Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK plus non-small-cell lung cancer (NSCLC)

F. Barlesi, A-M. C. Dingemans, J. C-H. Yang, S-H. I. Ou, J. S. Ahn, L. De Petris, B. Hughes, H. Lena, W. Bordogna, S. Golding, P. N. Morcos, B. Balas, A. Zeaiter, D-W. Kim

Research output: Contribution to journalConference Abstract/Poster in journalAcademic

Original languageEnglish
Article number1263P
Number of pages1
JournalAnnals of Oncology
Volume27
Issue numbersupp. 6
DOIs
Publication statusPublished - 1 Oct 2016

Cite this

Barlesi, F., Dingemans, A-M. C., Yang, J. C-H., Ou, S-H. I., Ahn, J. S., De Petris, L., Hughes, B., Lena, H., Bordogna, W., Golding, S., Morcos, P. N., Balas, B., Zeaiter, A., & Kim, D-W. (2016). Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK plus non-small-cell lung cancer (NSCLC). Annals of Oncology, 27(supp. 6), [1263P]. https://doi.org/10.1093/annonc/mdw383.63